Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 3
Table of contents:
Evaluation Report part 3 (pdf portfolio)
04 - Company clarification response
05 - Consultee submission -British Society Gatreoentrology
06 - Consultee submission -British Society Gastreoentrology
07 - Consultee submission -Crohn's and Colitis UK
08. Consultee submission - NHS Thanet CCG's & NHS South Kent Coast
09 - Consultee submission -Royal College of Physicians
10 - Consultee submission - UK Clinical Pharmacy Association (UKCPA)
11 - Patient expert personal perspective - Cleaver
12 - Patient expert personal perspective - Singh
13 - Clinical expert personal perspective - Hawthorn
14 - Evidence Review Group report prepared by Sheffield of Health and Related Research
15 - Evidence Review Group report - erratum
16 - Company factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 3
26 November 2014 (5.04 Mb 3 sec) |
This page was last updated: 26 November 2014